Sinclair Pharma Text-only version

France, Spain & Portugal
Sinclair Pharma France

The French market saw successful launches of Sebclair^®, Papulex^® Eau – a line extension of the anti-acne treatment Papulex^® and also the Méla´Aura products which are designed for ethnic skin. This resulted in a revenue contribution of £9.6m from Sinclair Pharma France which also incorporates the Spanish and Portuguese operation. The management of the export business from France has been moved to our marketing partner network to allow the French company to focus on its domestic market.

Italy
Sinclair Srl

Sinclair Srl contributed £2.6m to Sinclair Group revenues during the year. It saw the launch of Papulex^® cream as well as the B.lift and B.derm range, a line of anti-ageing and anti-wrinkle products, which were acquired from Syrio Pharma earlier in the year.

UK
Ashbourne Pharmaceuticals

Sinclair acquired Ashbourne Pharmaceuticals in September 2006. The revenue contribution from the UK this year was £1.5m.

This year saw the launches of Atopiclair® and Xclair^® and also the continued integration of the Ashbourne business into the Sinclair Group. There has also been a change in strategic focus following changes in recent legislation which will result in the practical disappearance of dispensing doctors. As a consequence we have accelerated the conversion of Ashbourne to a specialty pharma sales operation initially focused on dermatology, and will be rebranded to Sinclair Pharma UK Ltd going forwards.